Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06603623 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Trial of BHV-2100 for the Acute Treatment of Migraine
A Phase 2 study, sponsored by Biohaven Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 647
- Enrollment target
NCT06603623 is a Phase 2 study that has completed, run by Biohaven Therapeutics. The registered enrollment target is 647 participants.
The verdict
NCT06603623, a Phase 2 study, has completed, sponsored by Biohaven Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 647 participants
- Enrollment target
Study Summary
This study is designed to identify at least one dose of BHV-2100 that is safe and effective in reducing headache pain and other symptoms in the treatment of migraine.
Interventions
- DRUG Placebo
- DRUG BHV-2100
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 647 participants |
| Start Date | 2024-10-10 |
| Est. Completion | 2025-03-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06603623
The ClinicalTrials.gov registry entry for NCT06603623 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 647 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biohaven Therapeutics, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06603623 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06603623 about?
NCT06603623 is a clinical study titled "Efficacy and Safety Trial of BHV-2100 for the Acute Treatment of Migraine". This study is designed to identify at least one dose of BHV-2100 that is safe and effective in reducing headache pain and other symptoms in the treatment of migraine.
What is the current status of trial NCT06603623?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 647 participants. The study started on 2024-10-10. Estimated completion is 2025-03-28.
What interventions are being tested in trial NCT06603623?
The interventions under investigation include: Placebo (DRUG), BHV-2100 (DRUG).
Who is sponsoring clinical trial NCT06603623?
This trial is sponsored by Biohaven Therapeutics, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.